Inhibitor Therapeutics, Inc. Preferred Stock Dividends, Income Statement Impact
Inhibitor Therapeutics, Inc. (INTI) reported Preferred Stock Dividends, Income Statement Impact of $189.04 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2024-03-29
- Inhibitor Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2022-12-31 was $39.45K.
- Inhibitor Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2022-09-30 was $50.41K.
- Inhibitor Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2022-06-30 was $49.86K.
- Inhibitor Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2022-03-31 was $49.31K.
- Inhibitor Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2022 was $189.04K, a 5.48% decline from fiscal 2021.
- Inhibitor Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2021 was $200.00K.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2022-12-31 | $39.45K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $89.86K derived: sum of 2 quarters · filed 2024-03-29 | $139.73K derived: sum of 3 quarters · filed 2024-03-29 | $189.04K 10-K · filed 2024-03-29 |
| 2022-09-30 | $50.41K 10-Q · filed 2023-11-13 | $100.27K derived: sum of 2 quarters · filed 2023-11-13 | $149.59K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $49.86K 10-Q · filed 2023-08-11 | $99.18K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $49.31K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $200.00K 10-K · filed 2023-03-31 |